| Welcome to BiopolyMed, inc.,
BiopolyMed, Inc., (BPM) expresses its sincere thanks for
the acknowledgement and interest it has received.
BiopolyMed is a biotech company, which aims to focus its
technological efforts solely on the Drug Delivery System
(DDS) of protein/peptide drugs as well as small molecules
by focusing on the development of bioconjugation technology
with biocompatible polymers.
BiopolyMed has the strategies to develop the biocompatible
polymer technology for the second generation of bio-products
and core technology for anticancer drugs by enhancing
cell targeting and specific organ site targeting.
BiopolyMed also pursues further development of BPM's core
technology by business collaboration and strategic alliance
with pharmaceutical companies globally.
BiopolyMed will commit itself to do its best to contribute
in seeking 'better quality of life' using the DDS technologies
and work to become a prominent leader in the field of
the new, higher-valued biotech company.
BiopolyMed has outstanding scientific advisory board,
Professor Sung Wan Kim of University of Utah, USA, who
is well known internationally as a pioneer in the field
of gene delivery and biocompatible polymer, and Professor
Teruo Okano of Tokyo Women's Medical University in Japan,
who is a specialist in the area of tissue engineering
using biocompatible polymer.
BiopolyMed hopes to keep a humble attitude in the eyes
of God, and always remain as a hard working corporation
with continuous encouragement and interest.
CEO/President Myung-Ok Park